The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04975997




Registration number
Help: Registration number
NCT04975997
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
2/07/2021
Date registered
Help: Date registered
26/07/2021
Date last updated
Help: Date last updated
3/04/2026

Titles & IDs
Public title
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Scientific title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Additional trial identifiers [1] 0 0
U1111-1260-2872
Additional trial identifiers [2] 0 0
CC-220-MM-002
Universal Trial Number (UTN)
Trial acronym
EXCALIBER-RRMM
Related trial records

Health condition
Health condition(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab
Treatment: Drugs - Bortezomib
Treatment: Drugs - Iberdomide
Treatment: Drugs - Iberdomide
Treatment: Drugs - Iberdomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab

Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 - Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.

Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 -

Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 -

Active comparator: Daratumumab in combination with dexamethasone and bortezomib - Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone


Treatment: Drugs: Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Treatment: Drugs: Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

Treatment: Drugs: Bortezomib
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.

Treatment: Drugs: Iberdomide
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle

Treatment: Drugs: Iberdomide
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle

Treatment: Drugs: Iberdomide
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle

Treatment: Drugs: Dexamethasone
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8

Treatment: Drugs: Daratumumab
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Up to approximately 5 years
Primary outcome [2] 0 0
Minimal Residual Disease (MRD) negative Complete Response (CR) at any time
Timepoint [2] 0 0
Up to approximately 5 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [2] 0 0
Sustainability of Minimal Residual Disease (MRD) negativity
Timepoint [2] 0 0
Up to approximately 5 years
Secondary outcome [3] 0 0
Overall Response Rate (ORR)
Timepoint [3] 0 0
Up to approximately 5 years
Secondary outcome [4] 0 0
Time to response (TTR)
Timepoint [4] 0 0
Up to approximately 5 years
Secondary outcome [5] 0 0
Duration of Response (DoR)
Timepoint [5] 0 0
Up to approximately 5 years
Secondary outcome [6] 0 0
Time to Progression (TTP)
Timepoint [6] 0 0
Up to approximately 5 years
Secondary outcome [7] 0 0
Time to Next Treatment (TTNT)
Timepoint [7] 0 0
Up to approximately 5 years
Secondary outcome [8] 0 0
Progression-free Survival 2 (PFS2)
Timepoint [8] 0 0
Up to approximately 5 years
Secondary outcome [9] 0 0
Safety
Timepoint [9] 0 0
Up to approximately 5 years
Secondary outcome [10] 0 0
European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Timepoint [10] 0 0
Up to approximately 5 years
Secondary outcome [11] 0 0
European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Timepoint [11] 0 0
Up to approximately 5 years
Secondary outcome [12] 0 0
Recommended iberdomide dose for Stage 2
Timepoint [12] 0 0
Up to approximately 1 year
Secondary outcome [13] 0 0
Area under the plasma concentration-time curve from time zero to tau (AUC(TAU))
Timepoint [13] 0 0
Up to approximately 1 year
Secondary outcome [14] 0 0
Maximum plasma concentration (Cmax)
Timepoint [14] 0 0
Up to approximately 1 year
Secondary outcome [15] 0 0
Time to maximum plasma concentration (Tmax)
Timepoint [15] 0 0
Up to approximately 1 year

Eligibility
Key inclusion criteria
Inclusion Criteria

* Documented diagnosis of multiple myeloma (MM) and measurable disease.
* Received 1 to 2 prior lines of anti-myeloma therapy.
* Must have documented disease progression during or after their last anti-myeloma regimen.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria

* Any condition that confounds the ability to interpret data from the study.
* Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
* Known central nervous system involvement with MM.
* Prior therapy with iberdomide.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 813 - Birtinya
Recruitment hospital [2] 0 0
Local Institution - 812 - Douglas
Recruitment hospital [3] 0 0
Local Institution - 803 - Adelaide
Recruitment hospital [4] 0 0
Local Institution - 806 - Bedford Park
Recruitment hospital [5] 0 0
Local Institution - 802 - Clayton
Recruitment hospital [6] 0 0
Local Institution - 809 - East Melbourne
Recruitment hospital [7] 0 0
Local Institution - 801 - Melbourne
Recruitment hospital [8] 0 0
Local Institution - 811 - Murdoch
Recruitment hospital [9] 0 0
Local Institution - 807 - West Perth
Recruitment hospital [10] 0 0
Local Institution - 804 - Camperdown
Recruitment hospital [11] 0 0
Local Institution - 800 - Fitzroy
Recruitment hospital [12] 0 0
Local Institution - 808 - Garran
Recruitment postcode(s) [1] 0 0
4575 - Birtinya
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5042 - Bedford Park
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3001 - East Melbourne
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
6150 - Murdoch
Recruitment postcode(s) [9] 0 0
6005 - West Perth
Recruitment postcode(s) [10] 0 0
2050 - Camperdown
Recruitment postcode(s) [11] 0 0
3065 - Fitzroy
Recruitment postcode(s) [12] 0 0
ACT 2605 - Garran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Austria
State/province [26] 0 0
Graz
Country [27] 0 0
Austria
State/province [27] 0 0
Linz
Country [28] 0 0
Austria
State/province [28] 0 0
Salzburg
Country [29] 0 0
Austria
State/province [29] 0 0
Sankt Pölten
Country [30] 0 0
Austria
State/province [30] 0 0
Vienna
Country [31] 0 0
Belgium
State/province [31] 0 0
Bruges
Country [32] 0 0
Belgium
State/province [32] 0 0
Brussels
Country [33] 0 0
Brazil
State/province [33] 0 0
Paraná
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio Grande do Sul
Country [35] 0 0
Brazil
State/province [35] 0 0
São Paulo
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio de Janeiro
Country [37] 0 0
Canada
State/province [37] 0 0
Alberta
Country [38] 0 0
Canada
State/province [38] 0 0
British Columbia
Country [39] 0 0
Canada
State/province [39] 0 0
New Brunswick
Country [40] 0 0
Canada
State/province [40] 0 0
Newfoundland and Labrador
Country [41] 0 0
Canada
State/province [41] 0 0
Nova Scotia
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Canada
State/province [43] 0 0
Saskatchewan
Country [44] 0 0
China
State/province [44] 0 0
Hunan
Country [45] 0 0
China
State/province [45] 0 0
Jiangxi
Country [46] 0 0
China
State/province [46] 0 0
Shaanxi
Country [47] 0 0
China
State/province [47] 0 0
Shanghai Municipality
Country [48] 0 0
China
State/province [48] 0 0
Shanxi
Country [49] 0 0
China
State/province [49] 0 0
Zhejiang
Country [50] 0 0
China
State/province [50] 0 0
Beijing
Country [51] 0 0
China
State/province [51] 0 0
Changchun
Country [52] 0 0
China
State/province [52] 0 0
Chaoyang District
Country [53] 0 0
China
State/province [53] 0 0
Guangzhou
Country [54] 0 0
China
State/province [54] 0 0
Hangzhou
Country [55] 0 0
China
State/province [55] 0 0
Hangzhou, Zhejiang
Country [56] 0 0
China
State/province [56] 0 0
Harbin
Country [57] 0 0
China
State/province [57] 0 0
Nanjing
Country [58] 0 0
China
State/province [58] 0 0
Shanghai
Country [59] 0 0
China
State/province [59] 0 0
Shenyang
Country [60] 0 0
China
State/province [60] 0 0
Suzhu
Country [61] 0 0
China
State/province [61] 0 0
Tianjin
Country [62] 0 0
China
State/province [62] 0 0
Wuhan
Country [63] 0 0
China
State/province [63] 0 0
Xi'an
Country [64] 0 0
China
State/province [64] 0 0
Zhengzhou
Country [65] 0 0
Czechia
State/province [65] 0 0
Brno
Country [66] 0 0
Czechia
State/province [66] 0 0
Ostrava-Poruba
Country [67] 0 0
Czechia
State/province [67] 0 0
Prague
Country [68] 0 0
Denmark
State/province [68] 0 0
Aalborg
Country [69] 0 0
Denmark
State/province [69] 0 0
Odense
Country [70] 0 0
Denmark
State/province [70] 0 0
Roskilde
Country [71] 0 0
Finland
State/province [71] 0 0
Southwest Finland
Country [72] 0 0
Finland
State/province [72] 0 0
Helsinki
Country [73] 0 0
Finland
State/province [73] 0 0
Oulu
Country [74] 0 0
France
State/province [74] 0 0
Argenteuil
Country [75] 0 0
France
State/province [75] 0 0
La Roche-sur-Yon
Country [76] 0 0
France
State/province [76] 0 0
Lille
Country [77] 0 0
France
State/province [77] 0 0
Nancy
Country [78] 0 0
France
State/province [78] 0 0
Nantes
Country [79] 0 0
France
State/province [79] 0 0
Paris
Country [80] 0 0
France
State/province [80] 0 0
Pessac
Country [81] 0 0
France
State/province [81] 0 0
Rouen
Country [82] 0 0
France
State/province [82] 0 0
Toulouse
Country [83] 0 0
Germany
State/province [83] 0 0
Schleswig-Holstein
Country [84] 0 0
Germany
State/province [84] 0 0
Frankfurt am Main
Country [85] 0 0
Germany
State/province [85] 0 0
Hamburg
Country [86] 0 0
Germany
State/province [86] 0 0
Heidelberg
Country [87] 0 0
Germany
State/province [87] 0 0
Lübeck
Country [88] 0 0
Greece
State/province [88] 0 0
Achaea
Country [89] 0 0
Greece
State/province [89] 0 0
Achaia
Country [90] 0 0
Greece
State/province [90] 0 0
Athens
Country [91] 0 0
Greece
State/province [91] 0 0
Thessaloniki
Country [92] 0 0
India
State/province [92] 0 0
Andhra Pradesh
Country [93] 0 0
India
State/province [93] 0 0
Karnataka
Country [94] 0 0
India
State/province [94] 0 0
Kerala
Country [95] 0 0
India
State/province [95] 0 0
Maharashtra
Country [96] 0 0
India
State/province [96] 0 0
West Bengal
Country [97] 0 0
India
State/province [97] 0 0
Puducherry
Country [98] 0 0
Ireland
State/province [98] 0 0
Cork
Country [99] 0 0
Ireland
State/province [99] 0 0
Dublin
Country [100] 0 0
Ireland
State/province [100] 0 0
Galway
Country [101] 0 0
Israel
State/province [101] 0 0
Northern District
Country [102] 0 0
Israel
State/province [102] 0 0
Haifa
Country [103] 0 0
Israel
State/province [103] 0 0
Jerusalem
Country [104] 0 0
Israel
State/province [104] 0 0
Tel Aviv
Country [105] 0 0
Israel
State/province [105] 0 0
Tel Litwinsky
Country [106] 0 0
Italy
State/province [106] 0 0
Lazio
Country [107] 0 0
Italy
State/province [107] 0 0
Bologna
Country [108] 0 0
Italy
State/province [108] 0 0
Catania
Country [109] 0 0
Italy
State/province [109] 0 0
Genova
Country [110] 0 0
Italy
State/province [110] 0 0
Milan
Country [111] 0 0
Italy
State/province [111] 0 0
Novara
Country [112] 0 0
Italy
State/province [112] 0 0
Pavia
Country [113] 0 0
Italy
State/province [113] 0 0
Pisa
Country [114] 0 0
Italy
State/province [114] 0 0
Reggio Calabria
Country [115] 0 0
Italy
State/province [115] 0 0
Roma
Country [116] 0 0
Italy
State/province [116] 0 0
San Giovanni Rotondo FG
Country [117] 0 0
Italy
State/province [117] 0 0
Udine
Country [118] 0 0
Japan
State/province [118] 0 0
Ehime
Country [119] 0 0
Japan
State/province [119] 0 0
Ibaraki
Country [120] 0 0
Japan
State/province [120] 0 0
Tochigi
Country [121] 0 0
Japan
State/province [121] 0 0
Tokyo
Country [122] 0 0
Japan
State/province [122] 0 0
Yamanashi
Country [123] 0 0
Japan
State/province [123] 0 0
Aomori
Country [124] 0 0
Japan
State/province [124] 0 0
Chiba
Country [125] 0 0
Japan
State/province [125] 0 0
Fukuoka
Country [126] 0 0
Japan
State/province [126] 0 0
Kamogawa
Country [127] 0 0
Japan
State/province [127] 0 0
Kyoto
Country [128] 0 0
Japan
State/province [128] 0 0
Nagoya
Country [129] 0 0
Japan
State/province [129] 0 0
Okayama
Country [130] 0 0
Japan
State/province [130] 0 0
Osaka
Country [131] 0 0
Japan
State/province [131] 0 0
Osaka-sayama
Country [132] 0 0
Japan
State/province [132] 0 0
Sapporo
Country [133] 0 0
Japan
State/province [133] 0 0
Sendai
Country [134] 0 0
Japan
State/province [134] 0 0
Shibuya-ku
Country [135] 0 0
Japan
State/province [135] 0 0
Shinagawa-ku, Tokyo
Country [136] 0 0
Japan
State/province [136] 0 0
Toyohashi
Country [137] 0 0
Mexico
State/province [137] 0 0
Jalisco
Country [138] 0 0
Netherlands
State/province [138] 0 0
South Holland
Country [139] 0 0
Netherlands
State/province [139] 0 0
Amsterdam
Country [140] 0 0
Netherlands
State/province [140] 0 0
The Hague
Country [141] 0 0
Norway
State/province [141] 0 0
Bergen
Country [142] 0 0
Norway
State/province [142] 0 0
Oslo
Country [143] 0 0
Norway
State/province [143] 0 0
Trondheim
Country [144] 0 0
Poland
State/province [144] 0 0
Podlaskie Voivodeship
Country [145] 0 0
Poland
State/province [145] 0 0
Krakow
Country [146] 0 0
Poland
State/province [146] 0 0
Nowy Sacz
Country [147] 0 0
Poland
State/province [147] 0 0
Poznan
Country [148] 0 0
Poland
State/province [148] 0 0
Warsaw
Country [149] 0 0
Poland
State/province [149] 0 0
Walbrzych
Country [150] 0 0
Portugal
State/province [150] 0 0
Coimbra
Country [151] 0 0
Portugal
State/province [151] 0 0
Lisbon
Country [152] 0 0
Portugal
State/province [152] 0 0
Porto
Country [153] 0 0
South Korea
State/province [153] 0 0
Daegu
Country [154] 0 0
South Korea
State/province [154] 0 0
Gyeonggi-do
Country [155] 0 0
South Korea
State/province [155] 0 0
Hwasun-gun
Country [156] 0 0
South Korea
State/province [156] 0 0
Seoul
Country [157] 0 0
Spain
State/province [157] 0 0
Navarre
Country [158] 0 0
Spain
State/province [158] 0 0
Barcelona
Country [159] 0 0
Spain
State/province [159] 0 0
Cáceres
Country [160] 0 0
Spain
State/province [160] 0 0
Córdoba
Country [161] 0 0
Spain
State/province [161] 0 0
Madrid
Country [162] 0 0
Spain
State/province [162] 0 0
Málaga
Country [163] 0 0
Spain
State/province [163] 0 0
Murcia
Country [164] 0 0
Spain
State/province [164] 0 0
Oviedo
Country [165] 0 0
Spain
State/province [165] 0 0
Salamanca
Country [166] 0 0
Spain
State/province [166] 0 0
Santiago de Compostela
Country [167] 0 0
Spain
State/province [167] 0 0
Valencia
Country [168] 0 0
Spain
State/province [168] 0 0
Zaragoza
Country [169] 0 0
Sweden
State/province [169] 0 0
Borås
Country [170] 0 0
Sweden
State/province [170] 0 0
Helsingborg
Country [171] 0 0
Switzerland
State/province [171] 0 0
Chur
Country [172] 0 0
Switzerland
State/province [172] 0 0
Sankt Gallen
Country [173] 0 0
Taiwan
State/province [173] 0 0
Niao-Sung Hsiang Kaohsiung County
Country [174] 0 0
Taiwan
State/province [174] 0 0
Taichung
Country [175] 0 0
Taiwan
State/province [175] 0 0
Tainan, Taiana
Country [176] 0 0
Taiwan
State/province [176] 0 0
Taipei
Country [177] 0 0
Taiwan
State/province [177] 0 0
Taipei, Zhongzheng Dist.
Country [178] 0 0
Taiwan
State/province [178] 0 0
Taoyuan
Country [179] 0 0
Turkey (Türkiye)
State/province [179] 0 0
Ankara
Country [180] 0 0
Turkey (Türkiye)
State/province [180] 0 0
Istanbul
Country [181] 0 0
Turkey (Türkiye)
State/province [181] 0 0
Izmir
Country [182] 0 0
Turkey (Türkiye)
State/province [182] 0 0
Kurupelit
Country [183] 0 0
Turkey (Türkiye)
State/province [183] 0 0
Gaziantep
Country [184] 0 0
Turkey (Türkiye)
State/province [184] 0 0
Kayseri
Country [185] 0 0
United Kingdom
State/province [185] 0 0
Nottinghamshire
Country [186] 0 0
United Kingdom
State/province [186] 0 0
Belfast Northern Ireland
Country [187] 0 0
United Kingdom
State/province [187] 0 0
Birmingham
Country [188] 0 0
United Kingdom
State/province [188] 0 0
Canterbury Kent
Country [189] 0 0
United Kingdom
State/province [189] 0 0
Lancashire Blackpool
Country [190] 0 0
United Kingdom
State/province [190] 0 0
London
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Oxford
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Portsmouth
Country [193] 0 0
United Kingdom
State/province [193] 0 0
Sutton
Country [194] 0 0
United Kingdom
State/province [194] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
See Plan Description
Available to whom?
See Plan Description
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.